Hypercalcemia of Malignancy With Simultaneous Elevation in Serum Parath yroid Hormone-Related Peptide and 1,25-Dihydroxyvita min D in a Patient With Metastatic Renal Cell Carcinoma

Endocrine Practice

Volumn 15, Issue 3, 2009, Pages 234-239

  Shivnani, Sarika B ^a   Shelton, John M ^a   Richardson, James A ^a   Maalouf, Naim M ^b  

^a Department of Internal Medicine ^*

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PREDNISONE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CYTOPLASM; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER BIOPSY; MALE; METASTASIS; NEPHRECTOMY; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

EID: 67649198001     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.15.3.234     Document Type: Article

References (20)

1. Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med. 1997;103:134-145.
2. Broadus AE, Mangin M, Ikeda K, et al. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med. 1988;319:556-563.
3. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-379.
4. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CY. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med. 1984;100:1-6.
5. Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 1987;237:893-896.
6. Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005;20:1792-1803.
7. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer- associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980;303:1377-1383.
8. Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab. 1993;76:801-803.
9. Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab. 1996;81:607-611.
10. Rosenthal N, Insogna KL, Godsall JW, Smaldone L, Waldron JA, Stewart AF. Elevations in circulating 1,25- dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab. 1985;60: 29-33.
11. Papworth K, Grankvist K, Ljungberg B, Rasmuson T. Parathyroid hormone-related protein and serum calcium in patients with renal cell carcinoma. Tumour Biol. 2005; 26:201-206.
12. Klatte T, Said JW, Belldegrun AS, Pantuck AJ. Differential diagnosis of hypercalcemia in renal malignancy. Urology. 2007;70:179 e7-e8.
13. Gotoh A, Kitazawa S, Mizuno Y, et al. Common expression of parathyroid hormone-related protein and no correlation of calcium level in renal cell carcinomas. Cancer. 1993; 71:2803-2806.
14. Sourbier C, Massfelder T. Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett. 2006; 240:170-182.
15. Horiuchi N, Caulfield MP, Fisher JE, et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro [erratum in Science. 1988;239:128]. Science. 1987;238:1566-1568.
16. Budayr AA, Zysset E, Jenzer A, et al. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. J Bone Miner Res. 1994;9: 521-526.
17. Fukumoto S, Matsumoto T, Yamoto H, et al. Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production. Endocrinology. 1989;124:2057-2062.
18. Evans KN, Taylor H, Zehnder D, et al. Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol. 2004;165:807-813.
19. Hoekman K, Tjandra YI, Papapoulos SE. The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein. Cancer. 1991;68:642-647.
20. Van den Eynden GG, Neyret A, Fumey G, et al. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor. Bone. 2007;40:1166-1171.